Verapamil suppresses the inhomogeneity of electrical remodeling in a canine long-term rapid atrial stimulation model.
Verapamil is known to suppress shortening of the atrial effective refractory period (AERP) during relatively short-term atrial pacing, although the effect of a long-term stimulation model is unclear. The effect of verapamil on electrical remodeling was evaluated in a canine rapid atrial stimulation model. The right atrial appendage (RAA) was continuously paced (400 beats/min) for 2 weeks. Four pairs of electrodes were sutured at four atrial sites; the RAA, right atrium close to the inferior vena cava, Bachmann's bundle, and LA. AERP, AERP dispersion (AERPd), conduction time, and inducibility of AF were evaluated during the pacing phase and the recovery phase. The same protocol was performed under the administration of verapamil. In five control dogs, the AERP shortening was inhomogeneous and the shortening of the AERP was most prominent in the LA. AERPd increased during the rapid pacing phase by 5 +/- 2 ms, but recovered quickly in the recovery phase. The max AERPd was 46 +/- 4 ms in the control group and was larger than that in the verapamil group (31 +/- 3 ms, P = 0.001). At the LA site, the shortening of the AERP was decreased by verapamil administration (-19 +/- 3 vs -5 +/- 2 ms, P = 0.04). However, the AF inducibility was not significantly different between the two groups. The effect of verapamil on electrical remodeling was inhomogeneous, depending on the anatomic portion. As a result, AERPd widening during the rapid pacing phase was suppressed by verapamil, while the AF inducibility was unchanged.
Moriguchi
Masahiko
M
Department of Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan. mogu-masahiko@msd.biglobe.ne.jp
Niwano
Shinichi
S
Yoshizawa
Naoto
N
Kojima
Jisho
J
Inuo
Kimiatsu
K
Izumi
Tohru
T
D000704:Analysis of Variance; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000209:etiology; D002304:Cardiac Pacing, Artificial; D004195:Disease Models, Animal; D004285:Dogs; D006325:Heart Atria; D006329:Heart Conduction System / Q000187:drug effects* / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D012032:Refractory Period, Electrophysiological / Q000187:drug effects* / Q000502:physiology; D014700:Verapamil / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D014700:Verapamil